Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis - Neuschwander-Tetri, BA; Brunt, EM; Wehmeier, KR; Sponseller, CA; Hampton, K; Bacon, BR (J Hepatol., 2003)